NeuProScan is an innovative AI platform designed to predict the likelihood of dementia years before its onset. This technology addresses a critical gap in the current diagnostic process for Alzheimer's Disease.
- Alzheimer's diagnosis typically occurs after significant damage has been done, leading to reduced life expectancy and irreversible decline in quality of life.
- Current effective treatments require a positive Amyloid PET scan, which is expensive and challenging to prescribe widely, especially in early stages.
- NeuProScan empowers doctors to identify patients at the pre-clinical stage of Alzheimer's, utilizing more affordable MRI scans.
- This tool provides invaluable assistance to Neurologists and Radiologists, offering a secondary opinion that can guide decisions on advanced testing like PET scans or confirm initial diagnoses.
- NeuProScan enables earlier intervention, potentially slowing disease progression and improving patient outcomes.
- By leveraging MRI scans, it offers a more accessible and cost-effective approach compared to Amyloid PET scans.
- It serves as a critical decision-making tool for medical professionals in the early stages of Alzheimer's detection.